DE-CSC
9.10.2019 14:02:11 CEST | Business Wire | Press release
CSC announces a new domain name security intelligence API that can now bring together the power of CSC’s domain name security intelligence with other cloud-based security operations platforms. Debuting today at the FireEye Cyber Defense Summit 2019, this new solution will help the world's leading security experts, government leaders, and executives from various industries address important challenges in today’s cyber threat landscape, including the vulnerability of digital assets like domains, domain name systems (DNS), and digital certificates outside the firewall, noted by both companies as serious security blind spots.
Cyber threats such as domain name and DNS hijacking events enable criminals to redirect web traffic, email, apps, and other connections to services that rely on the hijacked domain name. The exploitation of weaknesses in DNS infrastructure is caused by a lack of controls, processes, and policies with most organizations. For clients leveraging a security operations platform or a SIEM, it’s now possible to display all your security intelligence in one place, adding security controls for domains, DNS, and digital certificates. This insight can help organizations mitigate the disruption of business continuity, leading to financial repercussions, loss of consumer trust, and sensitive data leaks. This is the first time any organization is able to integrate security controls for digital assets outside the firewall into their security operations platform including a SIEM.
“Customers today have vendor fatigue and are overwhelmed by managing multiple, disparate security solutions. With the CSC API accessible, our mutual customers will be able to monitor a suite of security events that occur outside their company’s firewall when integrated with the FireEye Helix Security Platform,” says Sean Morton, vice president of Customer Experience at FireEye. “Detecting risks such as DNS and domain name hijacking removes a significant blind spot in a company’s security strategy, providing valuable intelligence and alerts inside our security operations platform, ultimately increasing the efficiency and incident response times dealing with cyber threats.”
“As the world’s leading corporate domain name registrar, CSC is the only company in the unique position to provide visibility into the cyber risks associated with your business-critical digital assets outside the firewall—domains, DNS, and digital certificates. Coupled with other security operations platforms like FireEye Helix, our joint customers have access to a next generation security platform,” says Mark Calandra, senior vice president, CSC Digital Brand Services. “In response to the risk of DNS hijacking and other cyber crime noted in the Department of Homeland Security’s emergency directive and the UK National Cyber Security Centre’s security advisory , CSC’s advanced proprietary algorithms are designed to expose these blind spots that are a critical component for enhancing the security posture of any company with an online presence.”
The Cyber Defense Summit is being hosted by FireEye, and the conference takes place October 9-10, 2019, in Washington, D.C. CSC representatives will be in the exhibition hall to discuss CSC’s new Domain Name Security Intelligence API and its integration with FireEye Helix. We will also be discussing our recent Cyber Security Report highlighting the domain name security posture of global government defense contractors.
About CSC
CSC supports companies that are making significant investments in their security posture by exposing blind spots that exist within fundamental internet assets such as domain names, DNS, and digital certificates. By leveraging our proprietary security solutions, CSC secures companies from cyber threats to their digital assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties as a result of policies like GDPR. Along with internet assets, CSC protects online brands that are being exploited via counterfeit websites, fraud, and IP violations, and helps monitor and mitigate this, providing enforcement and advisory services to protect many of the world’s largest brands. Learn more at cscdigitalbrand.services .
About FireEye, Inc.
FireEye is the intelligence-led security company. Working as a seamless, scalable extension of customer security operations, FireEye offers a single platform that blends innovative security technologies, nation-state grade threat intelligence, and world-renowned Mandiant® consulting. With this approach, FireEye eliminates the complexity and burden of cyber security for organizations struggling to prepare for, prevent, and respond to cyber-attacks. FireEye has over 8,200 customers across 103 countries, including more than 50 percent of the Forbes Global 2000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005016/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
